City

Clinical trials near Phoenix, United States

Active studies with a listed research site in Phoenix, United States.

25active studies

13recruiting now

17countries represented

60largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 4

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Psoriatic Arthritis, Overweight or ObesityCondition

TirzepatideTreatment

Puerto Rico, United States55 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06864026See eligibility →

Recruiting nowPhase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Argentina, Australia42 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07215559See eligibility →

Recruiting nowPhase 4

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Psoriasis, Overweight or ObesityCondition

TirzepatideTreatment

United States39 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06857942See eligibility →

Recruiting nowNot applicable

Early Tracking of Childhood Health Determinants (ETCHED) Study

Diabetes Mellitus, ObesityCondition

Intervention not listedTreatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-09-01 · NCT03481829See eligibility →

Recruiting nowNot applicable

The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure

Obesity, Normal PhysiologyCondition

+200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat, fastingTreatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-08-28 · NCT05545306See eligibility →

Recruiting nowNot applicable

Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity

Obesity & OverweightCondition

Intervention not listedTreatment

United States3 locations

Foundation for the National Institutes of HealthSponsor

Updated 2026-08-20 · NCT07776678See eligibility →

Recruiting nowNot applicable

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

Obesity, Healthy VolunteerCondition

Fixed Mixed Meal Test, Adjusted Mixed Meal TestTreatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-08-18 · NCT06223555See eligibility →

Recruiting nowNot applicable

Adverse Outcomes and Mortality in Liver Transplant

End Stage Liver DIsease, SarcopeniaCondition

MAsSTreatment

United States1 locations

Mayo ClinicSponsor

Updated 2026-08-05 · NCT05477277See eligibility →

Recruiting nowPhase 4

Fibrosis Lessens After Metabolic Surgery

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver DiseaseCondition

Metabolic surgery, Incretin-Based TherapyTreatment

Brazil, Canada22 locations

The Cleveland ClinicSponsor

Updated 2026-07-31 · NCT06374875See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

Obesity, OverweightCondition

KAI-7535, PlaceboTreatment

Australia, United States36 locations

KaileraSponsor

Updated 2026-07-28 · NCT07497880See eligibility →

Recruiting nowPhase 2

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Overweight or Obesity and Elevated Liver FatCondition

Maridebart cafraglutide, PlaceboTreatment

United States23 locations

AmgenSponsor

Updated 2026-06-18 · NCT07441252See eligibility →

Recruiting nowPhase 3

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Overweight or Obesity, Atrial FibrillationCondition

Semaglutide, PlaceboTreatment

United States2 locations

University of ChicagoSponsor

Updated 2025-11-14 · NCT06499857See eligibility →

Active, not recruitingPhase 2

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

Obesity & Overweight, Mobility DisabilityCondition

Enobosarm, Semaglutide (Wegovy) weekly injectionTreatment

United States13 locations

Veru Inc.Sponsor

Updated 2026-09-04 · NCT07446998See eligibility →

Active, not recruitingPhase 2

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

ObesityCondition

Trevogrumab-Part A, Trevogrumab-Part B and Part CTreatment

Puerto Rico, United States60 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-09-01 · NCT06299098See eligibility →

Active, not recruitingPhase 2

Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment

Electric Stimulation Therapy, ObesityCondition

Transcranial Direct Current Stimulation (TDCS), Sham/no-stimulationTreatment

United States1 locations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Sponsor

Updated 2026-09-01 · NCT00739362See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Overweight, Type 2 DiabetesCondition

Petrelintide, PlaceboTreatment

United States48 locations

Zealand PharmaSponsor

Updated 2026-08-21 · NCT06926842See eligibility →

Active, not recruitingPhase 2

A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

VRB-101, PlaceboTreatment

United States20 locations

Verdiva Bio Dev LimitedSponsor

Updated 2026-08-04 · NCT07553299See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

LY3841136, TirzepatideTreatment

Argentina, United States52 locations

Eli Lilly and CompanySponsor

Updated 2026-07-17 · NCT06603571See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Obesity, OverweightCondition

RetatrutideTreatment

Argentina, Canada35 locations

Eli Lilly and CompanySponsor

Updated 2026-06-09 · NCT07357415See eligibility →

Active, not recruitingNot applicable

Preventing Diabetes in Latino Families

Type 2 Diabetes, ObesityCondition

Lifestyle InterventionTreatment

United States1 locations

Arizona State UniversitySponsor

Updated 2026-04-27 · NCT05228522See eligibility →

Active, not recruitingPhase 2

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Type 2 Diabetes, ObesityCondition

Tirzepatide, PlaceboTreatment

Argentina, Mexico40 locations

Eli Lilly and CompanySponsor

Updated 2026-03-23 · NCT06037252See eligibility →

Active, not recruitingNot applicable

Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide

Obesity, Weight Change TrajectoryCondition

Revita Duodenal Mucosal Resurfacing (DMR), ShamTreatment

United States32 locations

Fractyl Health Inc.Sponsor

Updated 2026-03-03 · NCT06484114See eligibility →

Active, not recruitingPhase 2

Aleniglipron Phase 2 Body Composition Study

Obesity, Overweight, or Chronic Weight ManagementCondition

aleniglipron or placeboTreatment

United States11 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-03-03 · NCT07169942See eligibility →

Active, not recruitingNot applicable

Using Signos mHealth Platform in Adults for Weight Management

Overweight and Obesity, Metabolic SyndromeCondition

Signos System, Standard Lifestyle EducationTreatment

United States5 locations

Signos IncSponsor

Updated 2024-10-08 · NCT06214221See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Phoenix, United States

Current studies

Related cities